|
Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia |
Dec 2023 |
Immunotherapy |
Aplastic Anemia |
|
Granulocyte transfusions in severe aplastic anemia |
Dec 2023 |
Haematologica |
Aplastic Anemia |
|
Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations |
Dec 2023 |
Journal of Blood Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy |
Dec 2023 |
Haematologica |
Aplastic Anemia |
|
Myelodysplastic syndromes with ring sideroblasts |
Oct 2023 |
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
|
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia |
Oct 2023 |
International Journal of Hematology |
Aplastic Anemia |
|
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT |
Oct 2023 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
|
Clinical decision‐making and treatment of myelodysplastic syndromes |
Oct 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
Oct 2023 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy |
Oct 2023 |
Annual Review of Pathology: Mechanisms of Disease |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
